Dei Gratia Labs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.18 M
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.10 M
- Revenue Growth 6.32%
- Profit Growth 32.20%
- Ebitda -34.33%
- Net Worth 0.27%
- Total Assets -2.66%
About Dei Gratia Labs
Dei Gratia Labs Private Limited (DGLPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 January 2006 and has a history of 19 years and one month. Its registered office is in Meerut, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.18 M.
The company has closed loans amounting to ₹5.10 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rajeev Sharma and Mamta Sharma serve as directors at the Company.
Company Details
- Location
Meerut, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U29297UP2006PTC031219
- Company No.
031219
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jan 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Dei Gratia Labs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Sharma  | Director | 12-Jan-2006 | Current |
| Mamta Sharma | Director | 10-Feb-2014 | Current |
Financial Performance of Dei Gratia Labs.
Dei Gratia Labs Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 6.32% increase. The company also saw a substantial improvement in profitability, with a 32.2% increase in profit. The company's net worth moved up by a moderate rise of 0.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dei Gratia Labs?
In 2020, Dei Gratia Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹5.10 M
Charges Breakdown by Lending Institutions
- Others : 0.30 Cr
- Bank Of Baroda : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Oct 2017 | Others | ₹3.00 M | Satisfied |
| 22 Nov 2013 | Bank Of Baroda | ₹2.10 M | Satisfied |
How Many Employees Work at Dei Gratia Labs?
Unlock and access historical data on people associated with Dei Gratia Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dei Gratia Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dei Gratia Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
